

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Re: Application of: David Morton, et al.  
Serial No.: 10/571,184  
Filed: July 17, 2006 as national phase of International Patent  
Application PCT/GB2004/003932, filed September 15, 2004  
For: **MUCOACTIVE AGENTS FOR TREATING A  
PULMONARY DISEASE**  
TC/A.U.: 1623  
Examiner: Eric OLSON  
Docket No. 4781.1077  
Customer No: 23280



Mail Stop: 313(c)  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

November 23, 2010

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**


S I R:

In accordance with Applicants' duty of disclosure under 37 C.F.R. §§ 1.56 and 1.97, Applicant hereby submits this Information Disclosure Statement, including nine (9) sheets of Form PTO-1449, for consideration by the Examiner in connection with the above-identified patent application.

The present Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b) before the mailing of a first Office Action on the merits. Accordingly, it is believed that no fee is due. If it is determined that any fees are due, the Examiner is authorized to charge said fees to Attorney Deposit Account No. 50-0552.

Applicants respectfully request that the references cited in the accompanying PTO 1449 form be considered and made of record. Applicants respectfully submit that the pending claims are patentable over all of the references made of record at this time.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By:   
Leslye B. Davidson  
Reg. No. 38,854

DAVIDSON, DAVIDSON & KAPPEL, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, NY 10018  
(212) 736-1940